Metformin in the Diastolic Dysfunction of Metabolic Syndrome (MET-DIME)
Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial
Sponsor: Centro Hospitalar de Vila Nova de Gaia/Espinho
A PHASE2 clinical study on Diastolic Dysfunction and Insulin Resistance, this trial is completed. The trial is conducted by Centro Hospitalar de Vila Nova de Gaia/Espinho and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Aug 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro Hospitalar de Vila Nova de Gaia/Espinho
- Merck Serono International SA
- Universidade do Porto
For direct contact, visit the study record on ClinicalTrials.gov .